HSBC Holdings’s Trevi Therapeutics TRVI Stock Holding History

HSBC Holdings’s Portfolio TRVI Stock Details TRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$205K	Buy	+17,034	New	+$191K	﹤0.01%	2601
2025 Q4	–	Sell	-41,634	Closed	-$372K	–	3163
2025 Q3	$372K	Sell	41,634 -20,805	-33%	-$156K	﹤0.01%	2242
2025 Q2	$342K	Buy	62,439 +34,691	+125%	+$216K	﹤0.01%	2365
2025 Q1	$173K	Sell	27,748 -17,005	-38%	-$81.1K	﹤0.01%	2658
2024 Q4	$184K	Buy	44,753 +843	+2%	+$2.7K	﹤0.01%	2743
2024 Q3	$144K	Buy	43,910 +24,298	+124%	+$72.2K	﹤0.01%	2722
2024 Q2	$60.8K	Buy	+19,612	New	+$54.5K	﹤0.01%	2801

Other funds holding TRVI

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

HSBC Holdings's TRVI Position: Q1 2026 in Review

HSBC Holdings opened a new position in Trevi Therapeutics (TRVI) in Q1 2026: 17,034 shares worth $205K. The stake represents ﹤0.01% of the portfolio and ranks #2601 among its holdings. This is a return to the name: HSBC Holdings previously reported a position in TRVI as recently as Q3 2025.

HSBC Holdings first reported a position in TRVI in Q2 2024 and has held it in 7 quarters since. The position peaked at $372K in Q3 2025. 198 funds tracked by Wall St. Rank hold TRVI as of Q1 2026.

HSBC Holdings held 17,034 shares of Trevi Therapeutics worth $205K as of Q1 2026.
Trevi Therapeutics was a new HSBC Holdings position in Q1 2026.
Trevi Therapeutics made up ﹤0.01% of HSBC Holdings's portfolio in Q1 2026, its #2601 holding.
HSBC Holdings first reported a position in Trevi Therapeutics in Q2 2024 and has held it in 7 quarters since.
HSBC Holdings's Trevi Therapeutics position peaked at $372K in Q3 2025.
198 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q1 2026.

Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.